Cynthia R. Osborne - Concepedia

Author

Cynthia R. Osborne

Also Known As

C Osborne, C. Osborne, Cynthia Osborne, Cynthia R C Osborne, Cynthia R Osborne, Cynthia R. C. Osborne, Cynthia R. Osborne, Cynthia R.C. Osborne

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Texas Oncology Memorial Sloan Kettering Cancer Center Virginia Oncology Associates Massachusetts General Hospital Rocky Mountain Cancer Centers

About

Cynthia R. Osborne is an author at Texas Oncology specializing in medicine, breast cancer, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	16	1.6K
2	Immunology	6	6	362
3	Cell Biology	5	5	213
4	Health Sciences	3	3	654
5	Engineering	1	1	223

Cynthia R. Osborne

Publications

Citations

H-Index

Page 1

	Year	Citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial Joyce O’Shaughnessy, Cynthia R. Osborne, John Pippen, Journal of Clinical Oncology Surgical OncologyBreast OncologyTumoral PathologyMalignant DiseaseMedicine	2009	243
Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities David W. Craig, Joyce O’Shaughnessy, Jeffrey Kiefer, Molecular Cancer Therapeutics Metastatic TnbcBreast OncologyEngineeringTumor HeterogeneityMedicine	2012	223
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues Songdong Meng, Debu Tripathy, Sanjay Shete, Proceedings of the National Academy of Sciences Gene AmplificationBreast OncologyImmunologyPathologyHer-2 Gene Status	2006	156
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer Jennifer R. Diamond, Carlos Becerra, Donald Richards, Breast Cancer Research and Treatment Breast OncologyMedicineAnti-frizzled Antibody VantictumabImmunologyPathology	2020	141
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer Aditya Bardia, Virginia Kaklamani, Sharon Wilks, Journal of Clinical Oncology	2021	106
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis Guy Jérusalem, Yeon Hee Park, Toshinari Yamashita, Cancer Discovery	2022	97
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling Frankie A. Holmes, Virginia Espina, Lance A. Liotta, BMC Research Notes	2013	74
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies H. Raftopoulos, Abderrahmane Laadem, Paul J. Hesketh, Supportive Care in Cancer	2015	65
Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial. Guy Jérusalem, Yeon Hee Park, Toshinari Yamashita, Journal of Clinical Oncology Breast OncologyBrain MetastasesCancer ManagementPathologyOncology	2021	52

Page 1